Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942981 · ClinicalTrials.gov registry record
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
A clinical trial of Schizophrenia and Schizoaffective Disorder, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 283
- Enrollment target
- 1
- Study location
NCT00942981 is a study of Schizophrenia and Schizoaffective Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 283 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00942981, a study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 283 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions. * The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people who have dopamine disorders (such as schizophrenia) and those who do not. Researchers are interested in studying the dopamine system to gain a better idea of how dopamine disorders develop, which may lead to better medical care for people with schizophrenia. Objectives: \- To study the amount and distribution of two types of dopamine receptors. Eligibility: * Individuals between the ages of 18 and 60 who have schizophrenia. * Healthy volunteers between the ages of 18 and 90. Design: * Participants will undergo a full screening, with physical and psychological history, a neurological examination, and blood and urine samples. * Participants will have a blood flow map of the brain recorded with a positron emission tomography (PET) brain scan. A magnetic resonance imaging (MRI) scan will also be performed to determine brain anatomy. * To study the amount and distribution of dopamine receptors in the brain, participants will receive a small amount of a radioactive chemical in the vein, followed by a PET scan. * The procedure will be performed twice in two separate sessions, once for \[18F\]fallypride and once for \[11C\]NNC-112.
Conditions Studied
Interventions
- DRUG PET
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2009-11-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942981
The ClinicalTrials.gov registry entry for NCT00942981 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which PET is the first listed.
NCT00942981 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00942981 about?
NCT00942981 is a clinical study titled "Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography". Background: * Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors ...
What is the current status of trial NCT00942981?
This trial is currently completed. The enrollment target is 283 participants. The study started on 2009-11-13.
What conditions does trial NCT00942981 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT00942981?
The interventions under investigation include: PET (DRUG).
Who is sponsoring clinical trial NCT00942981?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00942981 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.